InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) - Announcements

- Current share price for NSB : $0.059

ASX company news and announcements for NeuroScientific Biopharmaceuticals Ltd (NSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All NeuroScientific Biopharmaceuticals Ltd (NSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than NeuroScientific Biopharmaceuticals Ltd (NSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for NeuroScientific Biopharmaceuticals Ltd (NSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$23 Application for quotation of securities - NSB 27 Jun 2025 9:05AM $0.074 $0.059 fallen by 20.27%
$23 Application for quotation of securities - NSB 27 Jun 2025 9:01AM $0.074 $0.059 fallen by 20.27%
$23 Results of General Meeting 23 Jun 2025 11:02AM $0.080 $0.059 fallen by 26.25%
$23 Previous StemSmart Studies Demonstrate Clinical Response 19 Jun 2025 9:26AM $0.062 $0.059 fallen by 4.84%
$23 Notification of cessation of securities - NSB 18 Jun 2025 11:21AM $0.062 $0.059 fallen by 4.84%
$23 Proposed issue of securities - NSB 26 May 2025 5:22PM $0.053 $0.059 risen by 11.32%
$23 Letter to Shareholders & Proxy Form 23 May 2025 2:29PM $0.053 $0.059 risen by 11.32%
$23 Notice of General Meeting & Proxy Form 23 May 2025 2:25PM $0.053 $0.059 risen by 11.32%
$23 Special Access Program Set to Commence 23 May 2025 9:22AM $0.053 $0.059 risen by 11.32%
$23 Change of Director's Interest Notice 14 May 2025 9:25AM $0.053 $0.059 risen by 11.32%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 24 Apr 2025 9:14AM $0.050 $0.059 risen by 18%
$23 Proposed issue of securities - NSB 16 Apr 2025 9:12AM $0.035 $0.059 risen by 68.57%
$23 Proposed issue of securities - NSB 16 Apr 2025 9:11AM $0.035 $0.059 risen by 68.57%
$23 NeuroScientific to Acquire Leading Stem Cell Technology 16 Apr 2025 9:11AM $0.035 $0.059 risen by 68.57%
$23 Trading Halt 14 Apr 2025 9:47AM $0.035 $0.059 risen by 68.57%
$23 Half Yearly Report and Accounts 26 Feb 2025 5:27PM $0.039 $0.059 risen by 51.28%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 9:11AM $0.037 $0.059 risen by 59.46%
$23 Change of Registered Office Address 24 Jan 2025 11:33AM $0.036 $0.059 risen by 63.89%
$23 Notification of cessation of securities - NSB 22 Jan 2025 4:30PM $0.039 $0.059 risen by 51.28%
$23 Results of Annual General Meeting 6 Nov 2024 2:36PM $0.036 $0.059 risen by 63.89%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 29 Oct 2024 9:32AM $0.038 $0.059 risen by 55.26%
$23 Letter to Shareholders and Proxy Form 2 Oct 2024 3:54PM $0.039 $0.059 risen by 51.28%
$23 Notice of Annual General Meeting 2 Oct 2024 3:53PM $0.039 $0.059 risen by 51.28%
$23 Appendix 4G & Corporate Governance Statement 29 Aug 2024 7:21PM $0.042 $0.059 risen by 40.48%
$23 2024 Annual Report & Appendix 4E 29 Aug 2024 7:21PM $0.042 $0.059 risen by 40.48%

51 - 75 of 406 results

Page 3 of 17

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.